{"id":381,"date":"2025-10-16T13:07:05","date_gmt":"2025-10-16T13:07:05","guid":{"rendered":"https:\/\/cninmed.com\/en\/?p=381"},"modified":"2025-10-16T13:07:06","modified_gmt":"2025-10-16T13:07:06","slug":"china-bd-2025-leads-biolabs-and-dianthus-enters-a-1-billion-usd-license-on-dnth212-lbl-047-a-bifunctional-bdca2-and-baff-april-inhibitor","status":"publish","type":"post","link":"https:\/\/cninmed.com\/en\/2025\/381.html","title":{"rendered":"[China BD 2025] Leads Biolabs and Dianthus enters a 1 Billion USD License on DNTH212 (LBL-047), a bifunctional BDCA2 and BAFF\/APRIL inhibitor"},"content":{"rendered":"\n<p>Announced Date: 2025-10-16 (October 16, 2025)<\/p>\n\n\n\n<p>Licensor (Seller): Nanjing Leads Biolabs (China)<\/p>\n\n\n\n<p>Licensee (Buyer): \u00a0Dianthus Therapeutics (US)<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Asset Name: DNTH212 (LBL-047)<\/p>\n\n\n\n<p>Asset Modality: bifunctional fusion protein<\/p>\n\n\n\n<p>Asset Target: BDCA2 and BAFF\/APRIL inhibitor<\/p>\n\n\n\n<p>Potential Indication: multiple autoimmune disorders<\/p>\n\n\n\n<p>Current Stage: Phase 1 study ready<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Scope of Authority: <\/p>\n\n\n\n<p>Dianthus Therapeutics obtained exclusive rights to develop and commercialize DNTH212 globally outside of Greater China.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Payment Detail: <\/p>\n\n\n\n<p>Up to $38 million, comprised of $30 million in upfront and near-term milestone payments, additional $8 million milestone upon the initiation of a Dianthus-led Phase 1 study, <\/p>\n\n\n\n<p>Additional $962 million in total development and regulatory approval milestones.<\/p>\n\n\n\n<p>Sales-based milestones across multiple indications, as well as tiered royalties from mid-single digits up to a low double-digit on ex-Greater China net sales.<\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Link:<\/p>\n\n\n\n<p><a href=\"https:\/\/investor.dianthustx.com\/news-releases\/news-release-details\/dianthus-therapeutics-announces-exclusive-license-agreement\">Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 &amp; BAFF\/APRIL Inhibitor for Severe Autoimmune Diseases &#8211; Dianthus Therapeutics (dianthustx.com)<\/a><\/p>\n\n\n\n<p>.<\/p>\n\n\n\n<p>Note:<\/p>\n\n\n\n<p>Chinese Name of Nanjing Leads Biolabs, \u7ef4\u7acb\u5fd7\u535a<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Announced Date: 2025-10-16 (October 16, 2025) Licensor (Seller): Nanjing Leads Biolabs (China) Licensee (Buyer): \u00a0Dianthus Therapeutics &hellip; <a title=\"[China BD 2025] Leads Biolabs and Dianthus enters a 1 Billion USD License on DNTH212 (LBL-047), a bifunctional BDCA2 and BAFF\/APRIL inhibitor\" class=\"hm-read-more\" href=\"https:\/\/cninmed.com\/en\/2025\/381.html\"><span class=\"screen-reader-text\">[China BD 2025] Leads Biolabs and Dianthus enters a 1 Billion USD License on DNTH212 (LBL-047), a bifunctional BDCA2 and BAFF\/APRIL inhibitor<\/span>Read more<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-381","post","type-post","status-publish","format-standard","hentry","category-china-license-out"],"_links":{"self":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/381","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/comments?post=381"}],"version-history":[{"count":1,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/381\/revisions"}],"predecessor-version":[{"id":382,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/posts\/381\/revisions\/382"}],"wp:attachment":[{"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/media?parent=381"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/categories?post=381"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cninmed.com\/en\/wp-json\/wp\/v2\/tags?post=381"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}